CoreValve to present at JPMorgan 2008 Healthcare Conference
IRVINE, Calif. (Business Wire EON/PRWEB ) January 3, 2008 --
CoreValve announced today that its Chairman, CEO and Founder, Jacques
Séguin, M.D., Ph.D., will be presenting
at JPMorgan’s 26th
Annual Healthcare Conference being held January 7-10, 2008, at the
Westin St. Francis Hotel, San Francisco. Dr. Séguin’s
presentation, which is scheduled for 9:00 a.m. PST on Thursday,
January 10, will update investors about CoreValve’s
progress toward clinical adoption of its breakthrough ReValving®
System, which makes possible the replacement of an aortic heart valve
via a non-surgical transcatheter approach. “CoreValve is experiencing swift adoption of
its ReValving® System by leading
European physicians due to its ease of percutaneous implantation,”
said Dr. Séguin. “The
procedure usually takes just one to two hours and is performed generally
under local anesthesia in a cath lab setting. Initially, ReValving®
is focused only on the highest-risk patients. However, there is a
growing conviction among many in the medical community that ReValving®
is indeed the procedure by which diseased aortic valves of less-sick
patients will be treated in just three to five years.” About CoreValve CoreValve, Inc., is headquartered in Irvine, Calif. Its proprietary ReValving®
System allows both percutaneous aortic valve
replacement (PAVR) and transapical aortic valve
replacement (TAVR) and is intended to provide an alternative to
open-heart surgery. The ReValving® System
procedures are performed on the beating heart without cardiac assistance
or rapid pacing, and may result in less trauma to the patient. This
technology may also offer substantial cost-savings to the healthcare
system. The catheter-based ReValving® System
includes a proprietary framed/self-expanding tissue heart valve that is
specifically designed and engineered for transcatheter delivery. For
more information about CoreValve, visit the Company’s
Web site at www.corevalve.com. (Caution: the CoreValve ReValving® System
will not be available in the USA for clinical trials or for sale until
further notice.)
|
